Targeting glucocerebrosidase for disease-modifying treatments in Parkinson's disease
Lead Research Organisation:
University College London
Department Name: Clinical Neurosciences at Royal Free
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
People |
ORCID iD |
Anthony Schapira (Principal Investigator) |
Publications
Gegg ME
(2015)
No evidence for substrate accumulation in Parkinson brains with GBA mutations.
in Movement disorders : official journal of the Movement Disorder Society
Hockey LN
(2015)
Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition.
in Journal of cell science
Kilpatrick BS
(2016)
Endoplasmic reticulum and lysosomal Ca²? stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts.
in Cell calcium
Migdalska-Richards A
(2017)
Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.
in Synapse (New York, N.Y.)
Migdalska-Richards A
(2016)
Ambroxol effects in glucocerebrosidase and a-synuclein transgenic mice
in Annals of Neurology
Migdalska-Richards A
(2017)
The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice
in Brain
Morén C
(2019)
GBA mutation promotes early mitochondrial dysfunction in 3D neurosphere models.
in Aging
Sanchez-Martinez A
(2016)
Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.
in Scientific reports
Schapira A
(2015)
Glucocerebrosidase and Parkinson disease: Recent advances
in Molecular and Cellular Neuroscience